Table 4.
The abnormal nerve conduction study findings in patients with COVID-19 pneumonia
| Patients with pneumonia (n = 27) Mean ± SD (min–max) |
Patients without pneumonia (n = 45) Mean ± SD (min–max) |
p-value | |
|---|---|---|---|
| Age ( years) | 42.1 ± 9.4 (24–55) | 34.9 ± 8.8 (18–56) | 0.013* |
| Gender (F/M) | 13/14 | 34/15 | 0.06 |
| Median nerve F wave latency (ms) | 27.1 ± 3.5 (23.4–41.7) | 25.5 ± 1.9 (21.4–30.7) | 0.045* |
| Ulnar SNAP amplitude (μv) | 32.3 ± 15.4 (15–90) | 40.8 ± 16.4 (15–100) | 0.020* |
| Ulnar MCV (m/s) | 57.3 ± 4.5 (47–69) | 61.0 ± 5.2 (50–73) | 0.001* |
| Posterior tibial MCV (m/s) | 43.8 ± 3.7 (40–53) | 45.4 ± 3.7 (38–59) | 0.026* |
| Left p100 latency (ms) | 117.7 ± 12.0 (106–152) | 114.2 ± 11.1 (104–166) | 0.026* |
Nerve conduction study results of COVID-19 patients. Abbreviations: MCV motor conduction velocity, SNAP sensory nerve action potential. *Significant p values are presented in bold (p < 0.05)